中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 2
Feb.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(2): 359-364

Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis

DOI: 10.3969/j.issn.1001-5256.2022.02.020
  • a.

    Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

  • b.

    Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

  • c.

    Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Research funding:

2019 Chongqing Technology Innovation and Application Development Project (cstc2019jscx-msxmX0117)

More Information
  • Corresponding author: WANG Xiaomei, 300394@hospital.cqmu.edu.cn
  • Received Date: 2021-06-22
  • Accepted Date: 2021-08-12
  • Published Date: 2022-02-20
    Abstract
  •   Objective  To investigate the risk factors for covert hepatic encephalopathy (CHE) in patients with liver cirrhosis and their influence on prognosis.  Methods  A total of 416 patients with liver cirrhosis who were hospitalized in a grade A tertiary hospital in Chongqing from September 2019 to June 2020 were enrolled in the study, and according to the presence or absence of CHE, they were divided into CHE group with 212 patients and non-CHE group with 204 patients. Clinical data and laboratory examination results were collected, and follow-up was performed for 6 months. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test, the continuous correction chi-square test, and the Mann-Whitney U test were used for comparison of categorical data between groups. Univariate and multivariate logistic regression analyses were used to analyze the risk factors for CHE.  Results  The incidence rate of CHE was 51%. The univariate analysis showed that age, course of disease, the medical history of hepatic encephalopathy (HE), infection, ascites, electrolyte disturbance, hepatorenal syndrome, Child-Pugh class, prothrombin time, total bilirubin, creatinine, platelet, prothrombin activity, albumin, and Model for End-stage Liver Disease (MELD) score were the influencing factors for CHE (all P < 0.05). The multivariate logistic regression analysis showed that the medical history of HE (OR=10.848, 95% CI: 4.971-23.674, P < 0.05), transjugular intrahepatic portosystemic shunt (TIPS) (OR=4.334, 95%CI: 1.203-15.621, P < 0.05), Child-Pugh class (OR=4.968, 95%CI: 1.299-18.992, P < 0.05), and MELD score (OR=1.253, 95%CI: 1.161-1.352, P < 0.05) were independent predictive factors for CHE (P < 0.05). The follow-up study showed that CHE had an effect on the short-or medium-term readmission, HE, and death of patients (all P < 0.05).  Conclusion  CHE has a relatively high incidence rate and greatly affects the prognosis of patients with liver cirrhosis. The development of CHE should be taken seriously in patients with a past history of HE, a history of TIPS, Child-Pugh class C liver function, and a high MELD score, and identification, screening, and intervention should be performed as early as possible to improve the prognosis of patients with liver cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    XU L, LI M, NAN SY. Study on illness uncertainty and influential factors of inpatients with cirrhosis and their family caregivers[J]. Chin J Nurs, 2020, 55(8): 1206-1211. DOI: 10.3761/j.issn.0254-1769.2020.08.018.

    许丽, 李萌, 南士英. 肝硬化住院患者及家属疾病不确定感现状及影响因素的研究[J]. 中华护理杂志, 2020, 55(8): 1206-1211. DOI: 10.3761/j.issn.0254-1769.2020.08.018.
    [2]
    ELWIR S, RAHIMI RS. Hepatic encephalopathy: An update on the pathophysiology and therapeutic options[J]. J Clin Transl Hepatol, 2017, 5(2): 142-151. DOI: 10.14218/JCTH.2016.00069.
    [3]
    HU XP, GAO J. International normalized ratio and model for end-stage liver disease score for predicting short-term prognosis of cirrhotic patients with hepatic encephalopathy[J]. J Third Milit Med Univ, 2019, 41(14): 1374-1380. DOI: 10.16016/j.1000-5404.201901232.

    胡小鹏, 高建. 国际标准化比值和终末期肝病模型评分对并发肝性脑病的肝硬化患者短期预后的预测价值[J]. 第三军医大学学报, 2019, 41(14): 1374-1380. DOI: 10.16016/j.1000-5404.201901232.
    [4]
    VILSTRUP H, AMODIO P, BAJAJ J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European[J]. Hepatology, 2014, 60(2): 715-735. DOI: 10.1002/hep.27210.
    [5]
    AGRAWAL S, UMAPATHY S, DHIMAN RK. Minimal hepatic encephalopathy impairs quality of life[J]. J Clin Exp Hepatol, 2015, 5(Suppl 1): S42-S48. DOI: 10.1016/j.jceh.2014.11.006.
    [6]
    LIAO W, TANG Y, WANG CY, et al. Sleep and cognition and risk factors in patients with hepatitis B cirrhosis complicated with occult hepatic encephalopathy[J]. Clin J Med Offic, 2020, 48(4): 420-421. DOI: 10.16680/j.1671-3826.2020.04.21.

    廖威, 唐艳, 王春燕, 等. 乙肝肝硬化合并隐匿性肝性脑病患者睡眠和认知情况及危险因素研究[J]. 临床军医杂志, 2020, 48(4): 420-421. DOI: 10.16680/j.1671-3826.2020.04.21.
    [7]
    STEPANOVA M, MISHRA A, VENKATESAN C, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009[J]. Clin Gastroenterol Hepatol, 2012, 10(9): 1034-1041. e1. DOI: 10.1016/j.cgh.2012.05.016.
    [8]
    PÉREZ-MATOS MC, JIANG ZG, TAPPER EB. Factors that affect results of psychometric tests to identify patients with minimal hepatic encephalopathy[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1836-1838. DOI: 10.1016/j.cgh.2018.03.010.
    [9]
    STINTON LM, JAYAKUMAR S. Minimal hepatic encephalopathy[J]. Can J Gastroenterol, 2013, 27(10): 572-574. DOI: 10.1155/2013/547670.
    [10]
    NABI E, THACKER LR, WADE JB, et al. Diagnosis of covert hepatic encephalopathy without specialized tests[J]. Clin Gastroenterol Hepatol, 2014, 12(8): 1384-1389. e2. DOI: 10.1016/j.cgh.2013.12.020.
    [11]
    LABENZ C, BEUL L, TOENGES G, et al. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy[J]. Eur J Intern Med, 2019, 60: 96-100. DOI: 10.1016/j.ejim.2018.08.008.
    [12]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [13]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
    [14]
    LI SW, WANG K, YU YQ, et al. Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China[J]. World J Gastroenterol, 2013, 19(46): 8745-8751. DOI: 10.3748/wjg.v19.i46.8745.
    [15]
    ZENG X, LI XX, SHI PM, et al. Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients[J]. J Gastroenterol Hepatol, 2019, 34(10): 1843-1850. DOI: 10.1111/jgh.14656.
    [16]
    QIAN ZP, YANG Y. Study on the current situation and risk factors of minimal hepatic encephalopathy in patients with liver cirrhosis[J]. Chin J Nurs, 2020, 55(6): 872-876. DOI: 10.376l/-issn.0254-1769.2020.06.015.

    钱珠萍, 杨艳. 肝硬化患者发生轻微型肝性脑病现状及影响因素研究[J]. 中华护理杂志, 2020, 55(6): 872-876. DOI: 10.376l/-issn.0254-1769.2020.06.015.
    [17]
    MINA A, MORAN S, ORTIZ-OLVERA N, et al. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis[J]. Hepatol Res, 2014, 44(10): E92-E99. DOI: 10.1111/hepr.12227.
    [18]
    AMPUERO J, MONTOLIÚ C, SIMÓN-TALERO M, et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression[J]. J Gastroenterol Hepatol, 2018, 33(3): 718-725. DOI: 10.1111/jgh.13917.
    [19]
    PERAZZO JC, TALLIS S, DELFANTE A, et al. Hepatic encephalopathy: An approach to its multiple pathophysiological features[J]. World J Hepatol, 2012, 4(3): 50-65. DOI: 10.4254/wjh.v4.i3.50.
    [20]
    SAAB S. Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy[J]. Int J Gen Med, 2015, 8: 165-173. DOI: 10.2147/IJGM.S81878.
    [21]
    WANG AJ, PENG AP, LI BM, et al. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients[J]. World J Gastroenterol, 2017, 23(34): 6321-6329. DOI: 10.3748/wjg.v23.i34.6321.
    [22]
    YOSHIMURA E, ICHIKAWA T, MIYAAKI H, et al. Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy[J]. Biomed Rep, 2016, 5(2): 193-198. DOI: 10.3892/br.2016.702.
    [23]
    RIGGIO O, AMODIO P, FARCOMENI A, et al. A model for predicting development of overt hepatic encephalopathy in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2015, 13(7): 1346-1352. DOI: 10.1016/j.cgh.2014.12.025.
    [24]
    LABENZ C, TOENGES G, HUBER Y, et al. Development and validation of a prognostic score to predict covert hepatic encephalopathy in patients with cirrhosis[J]. Am J Gastroenterol, 2019, 114(5): 764-770. DOI: 10.14309/ajg.0000000000000121.
    [25]
    TAPPER EB, PARIKH ND, SENGUPTA N, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis[J]. Hepatology, 2018, 68(4): 1498-1507. DOI: 10.1002/hep.29628.
    [26]
    BALE A, PAI CG, SHETTY S, et al. Prevalence of and factors associated with minimal hepatic encephalopathy in patients with cirrhosis of liver[J]. J Clin Exp Hepatol, 2018, 8(2): 156-161. DOI: 10.1016/j.jceh.2017.06.005.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (591) PDF downloads(61) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return